The global transrectal ultrasound (TRUS) market is expected to grow at a steady CAGR of around 6% during the forecast period. The market growth is driven by the rising prevalence of prostate cancer, ...

Arnhem, The Netherlands - Using Magnetic Resonance Imaging-Ultrasound (MRIUS)- guided prostate biopsy has high sensitivity to detect prostate abnormalities compared with transrectal ultrasonography ...

Transrectal ultrasound (TRUS) examination of the prostate is the established technique used to obtain systematic core biopsies of prostatic tissue for histological examination. This is usually to ...

Active surveillance (AS) is commonly based on standard 10–12-core prostate biopsies, which misclassify ~50% of cases compared with radical prostatectomy. We assessed the value of multiparametric ...

Less than 1% of patients who underwent the procedure under local analgesia and without antibiotic prophylaxis experienced post-biopsy infection, a study found. Transperineal magnetic resonance imaging ...

Transrectal ultrasound (TRUS)—guided prostate biopsy is currently considered the standard technique for obtaining tissue to make a histological diagnosis of prostatic carcinoma. Infectious ...

Repeated Bone-Targeted Therapy for Hormone-Refractory Prostate Carcinoma: Randomized Phase II Trial With the New, High-Energy Radiopharmaceutical Rhenium-188 Hydroxyethylidenediphosphonate Purpose: ...

Well demarcated hypoechoic areas in suspicious regions on MRI identify men more likely to have Gleason 7 or higher prostate cancer found on biopsy. Ultrasound characteristics of prostate regions that ...

Under adequate local anesthesia, the size of the transrectal ultrasound probe made no difference to pain perception during transrectal ultrasound guided prostate biopsy, according to a PubMed report.

Here's welcome news for men of a certain age: new results support a less invasive approach to investigations for suspicion of prostate cancer. An approach using MRI of the prostate followed by ...

Findings from a recent study challenge a push to reclassify low grade prostate cancer, Biopsy Gleason Grade Group 1, as “benign.” Anthony D’Amico, MD, PhD, chief of genitourinary radiation oncology at ...